Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study

References

• Goetghebeur M, Landry PA, Han D, et al. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol 2007;18:27-34
   PubMed Web of Science ®Google Scholar
• Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Contr & Hosp Epidemiol 2000;21:510-15
   PubMed Web of Science ®Google Scholar
• Hu F, Zhu D, Wang F. CHINET surveillance of bacterial resistance in China. China J Infect Chemother 2011;12:321-9
   Google Scholar
• Liu YN, Cao B, Wang H, et al. [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese J Tuberculosis Respir Dis 2012;35:739-46
   PubMedGoogle Scholar
• Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008;36(4 Suppl):S216-23
   PubMed Web of Science ®Google Scholar
• Sun W, Chen H, Liu Y, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrobial Agents Chemother 2009;53:3642-9
   PubMed Web of Science ®Google Scholar
• Hu J, Ma XX, Tian Y, et al. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive staphylococcus aureus clinical isolates in Northeast China. PloS One 2013;8:e73300
   PubMed Web of Science ®Google Scholar
• Zyvox® [package insert]. New York, NY: Pfizer Inc. 2012
   Google Scholar
• Itani KM, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010;199:804-16
   PubMed Web of Science ®Google Scholar
• Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrobial Chemother 2007;60:1361-9
   PubMed Web of Science ®Google Scholar
• Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005;189:425-8
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis Offl Publ Infect Dis Soc Am 2012;54:621-9
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, et al. Acute Dialysis Quality Initiative w: acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care (London, England) 2004;8:R204-12
   PubMed Web of Science ®Google Scholar
• Efron B. An introduction to the Bootstrap. New York: Chapman and Hall, 1993
   Google Scholar
• Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves–facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15
   PubMed Web of Science ®Google Scholar
• Notice of medicine and pharmaceutical market order rectification. Available from: http://www.sdpc.gov.cn/zfdj/jggg/zyfw/t20060602_128839.htm. Accessed October 3 2015
   Google Scholar
• A notification regarding the promoting of the reform in drug price at country level public hospital. Available from: http://www.ndrc.gov.cn/zcfb/zcfbtz/2012tz/t20120919_505765.htm. Accessed October 3 2015
   Google Scholar
• Niederman MS CJ SC, Wan Y, Gao X, et al. Incidence of renal failure and associated economic burden among patients with nosocomial pneumonia caused by methicillin resistant staphylococcus aureus (MRSA-NP) treated with linezolid or vancomycin: a secondary analysis of a multi-center randomized double-blind clinical trial. San Deigo, CA: IDWeek, 2012
   Google Scholar
• Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin*. Crit Care Med 2004;32:137-43
   PubMed Web of Science ®Google Scholar
• De Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection 2009;37:123-32
   PubMed Web of Science ®Google Scholar
• Cao Ja, Su Tb, Li Xb. Acute kidney injury caused by anti-infective drugs. Adverse Drug React 2010;12:325-8
   Google Scholar
• Che M, Yan Y, Zhang Y, et al. [Analysis of drug-induced acute renal failure in Shanghai]. Zhonghua Yi Xue Za Zhi 2009;89:744-9
   PubMedGoogle Scholar
• Du B, Chen DC, Liu DW. [Efficacy and nephrotoxicity of vancomycin in the treatment of Gram positive infections]. Chin Critical Care Med 2003;15:32-4
   Google Scholar
• Fang Y, Ding X, Zhong Y, et al. Acute kidney injury in a Chinese hospitalized population. Blood Purif 2010;30:120-6
   PubMed Web of Science ®Google Scholar
• Julián-Mauro JC, Cuervo J, Rebollo P, et al. Employment status and indirect costs in patients with renal failure: differences between different modalities of renal replacement therapy. Off Publ Spanish Soc Nephrol 2013;33:333-41
   Google Scholar
• Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management & quest. Kid Int 2005;68:1808-14
   PubMed Web of Science ®Google Scholar
• Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Contr 2008;36(4 Suppl):S93-100
   PubMed Web of Science ®Google Scholar
• Zhuo C, Xu YC, Xiao SN, et al. Glycopeptide minimum inhibitory concentration creep among meticillin-resistant Staphylococcus aureus from 2006–2011 in China. Int J Antimicrob Agents 2013;41:578-81
   PubMed Web of Science ®Google Scholar
• Zhang X, Hu Q, Yuan W, et al. First report of a sequence type 239 vancomycin-intermediate Staphylococcus aureus isolate in Mainland China. Diagn Microbiol Infect Dis 2013;77:64-8
   PubMed Web of Science ®Google Scholar
• Grau S, Rubio-Terres C. Pharmacoeconomics of linezolid. Exp Opin Pharmacother 2008;9:987-1000
   PubMed Web of Science ®Google Scholar
• Vinken AG, Li JZ, Balan DA, et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am J Therapeut 2003;10:264-74
   PubMedGoogle Scholar